ClinicalTrials.gg
CompletedNCT05536024Updated Oct 20, 2026

Combing a Deep Learning-Based Radiomics With Liquid Biopsy for Preoperative and Non-invasive Diagnosis of Glioma

An observational study in Glioma (Diagnosis), Liquid Biopsy and Deep Learning, sponsored by Second Affiliated Hospital of Nanchang University. Completed at 2 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Second Affiliated Hospital of Nanchang University · Observational

How we know

Updated Oct 20, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
68
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Glioma with a site in China — 70 open to participants now, 82 under way, 3 of them phase 3. Glioma · China.

Enrollment
39th of 50
68 · median 345
Started
2022
with 19 others
Observational
50 of 162
24 open now
Registered
84th of 162
by date

Among the 162 studies in Glioma with a site in China, this one is the 39th largest by enrollment of the 50 observational ones that give a count, is one of 20 that started in 2022, is one of 50 observational ones, and was the 84th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

70 of the 162 studies in Glioma with a site in China are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Glioma with a site in China, or all of them as a file.
02

Study summary

This registry has the following objectives. First, according to the guidance of 2021 WHO of CNS classification, we constructed and externally tested a multi-task DL model for simultaneous diagnosis of tumor segmentation, glioma classification and more extensive molecular subtype, including IDH mutation, ATRX deletion status, 1p19q co-deletion, TERT gene mutation status, etc. Second, based on the same ultimate purpose of liquid biopsy and radiomics, we innovatively put forward the concept and idea of combining radiomics and liquid biopsy technology to improve the diagnosis of glioma. And through our study, it will provide some clinical validation for this concept, hoping to supply some new ideas for subsequent research and supporting clinical decision-making.

Read the detailed description

Gliomas are the most common primary intracranial malignancies, accounting for 27% of all primary brain tumors, and approximately 100,000 people are diagnosed with diffuse gliomas worldwide each year. To date, "integrated diagnosis" was considered the gold standard for glioma diagnosis, which combines histopathology, molecular pathology, and World Health Organization (WHO) grade. Previous glioma diagnostic criteria have primarily relied on histopathological biopsies, while histological classification has traditionally been determined based on tumor morphology, resulting in intra-observer variability due to intra-tumor spatial heterogeneity and sampling errors. In addition, Traditional histopathology is somewhat difficult to explain why patients with the same pathology have significantly different survival. Over the past decade, advances in molecular pathology and histopathology detection techniques have deepened our understanding in the molecular features and biology of gliomas. Increasing evidence revealed the important role of molecular status in the " integrated diagnosis" of glioma. In particular, after the concept of molecular diagnosis was proposed by the 2016 WHO Central Nervous System (CNS) classification, the 2021 CNS classification (CNS5) reemphasized the importance of several molecular biomarkers in gliomas diagnosis and treatment guidance, including isocitrate dehydrogenase gene (IDH ) mutation status, alpha-thalassemia/mental retardation syndrome X-linked (ATRX) deletion status, 1p19q deletion status, telomerase reverse transcriptase (TERT) promoter mutation, etc. Which the objective is to classify the tumor subtypes more systematically, and categorize the glioma patients with similar efficacy and prognosis into a subgroup.

The current standard of therapy for gliomas is surgical resection followed by radiotherapy and/or chemotherapy based on clinical and tumor grade and molecular characteristics. Preoperatively non-invasive and accurate early " integrated diagnosis" will bring great benefits to the treatment and prognosis of patients, especially for those with special tumor location that cannot receive craniotomy or needle biopsy. Such special patients can take experimental radiotherapy and chemotherapy based on non-invasive diagnosis results. Although diagnostic criteria for molecular information in gliomas are often based on tissue biopsy, other techniques, such as radiomics, radiogenomics, and liquid biopsy, have shown promise. At present, conventional magnetic resonance imaging (MRI) scans are still the main method to assist in the diagnosis of gliomas, including pre- and post- contrast T1w, T2w, and T2w-FLAIR. Multimodal radiomics based on deep learning (DL) can analyze patterns of intratumor heterogeneity and tumor imaging features that are imperceptible by the human eye, so as to conduct " integrated prediction" of gliomas18. Up to now, most studies have focused on using ML algorithms to construct novel radiomic model to predict glioma, R van der Voort et al. developed the multi-task conventional neural network (CNN) model and achieved a glioma grade (II/III/IV) with AUC of 0.81, IDH-AUC of 90%, 1p19q co-deletion AUC of 0.85 in the test set. The best DL model developed by Matsui et al. achieved an overall accuracy of 65.9% in predicting IDH mutation and 1p/19q co-deletion. Also, the multi-task CNN model constructed by Decuyper et al. achieved 94%, 86%, and 87% accuracy in predicting grades, IDH mutations, and 1p/19q co-deletion states in external validation. The model constructed by Luo et al. achieved 83.9% and 80.4% in external tests for histological and molecular subtype diagnosis. In addition to the "integrated prediction", there exists many models that only predicting glioma grading or single molecular markers. Meanwhile, previous studies were based on the 2016 CNS classification for glioma grading and molecular subtypes prediction. Therefore, a multi-task DL radiomics model for preoperatively and non-invasively predicting glioma grading and more extensive molecular markers is urgently needed according to the latest 2021 CNS classification.

Although radiomics has showed some feasibility in predicting tumor molecular pathology, it is ridiculous to administer precision targeted therapy solely on the basis of this prediction. Therefore, we hope to provide more clinical evidence for the molecular pathological diagnosis of gliomas patients by using liquid biopsy technique as an important complement of radiomics. Circulating tumor cell (CTC), as one of the liquid biopsy techniques, shares the same final objective to preoperatively non-invasive and accurate diagnosis of gliomas.

Based on the several limitations of the current diagnostic models of glioma, and the combined methods of radiomics and liquid biopsy have great potential to non-invasive diagnose glioma grading and molecular markers since they are both easy to perform. Furthermore, to our knowledge, there has been no study of preoperative non-invasive diagnosis of glioma in the context of liquid biopsy-assisted radiomics.

Therefore, this study has the following objectives. First, according to the guidance of 2021 WHO of CNS classification, we constructed and externally tested a multi-task DL model for simultaneous diagnosis of tumor segmentation, glioma classification and more extensive molecular subtype, including IDH mutation, ATRX deletion status, 1p19q co-deletion, TERT gene mutation status, etc. Second, based on the same ultimate purpose of liquid biopsy and radiomics, we innovatively put forward the concept and idea of combining radiomics and liquid biopsy technology to improve the diagnosis of glioma. And through our study, it will provide some clinical validation for this concept, hoping to supply some new ideas for subsequent research and supporting clinical decision-making.

03

Conditions studied

  • Glioma (Diagnosis)
  • Liquid Biopsy
  • Deep Learning

Browse trials for

Keywords

  • Glioma
  • Diagnostic model
  • radiomic
  • liquid biopsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with newly diagnosed glioma that receiving surgical resection or needle biopsy accoding to 2021 WHO of CNS classfication

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • glioma patients with postoperative pathological examination
  • age >18 years old
  • without any radiotherapy and/or chemotherapy prior to preoperative MRI scan
  • receiving surgical resection or needle for the first diagnosis
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Non gliomas
  • Without any preoperatiev MRI scan in Imaging Record System
  • Or receiving radiotherapy and/or chemotherapy prior to preoperative MRI scan
  • Rejecting surgical resection or needle
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
68 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • glioma patients

    This study includes the glioma patients aged over 18 years, receiving surgical resection or needle biopsy for the first time, and without any radiotherapy and/or chemotherapy prior to preoperative MRI scan. All included glioma patients were redefined or newly diagnosed according to the 2021 WHO of CNS classification.

    Diagnostic Test: Prediction of glioma grading and molecular subtype

Interventions

  • Diagnostic testPrediction of glioma grading and molecular subtype

    Prediction of WHO grading(II/III/IV), IDH gene mutation status, ATRX deletion status, 1p/19q deletion status, CDKN2A/B homozygous deletion status, TERT gene mutation status, epidermal growth factor receptor (EGFR) mutation status, chromosome 7gain and chromosome 10 less status, H3F3A G34 (H3.3 G34) mutation status, H3 K27M mutation status

06

What researchers measure

Primary outcomes

  1. AUC value of prediction performance

    AUC=(Sensitivity+Specificity)-1

    Time frame: 1 year

  2. Dice coefficient for evaluating semgmentation performance

    Dice=2TP/(2TP+FP+FN)

    Time frame: 1 year

07

Study locations

2 sites
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330000, China
08

References and documents

Publications

  • Hu P, Xu L, Qi Y, Yan T, Ye L, Wen S, Yuan D, Zhu X, Deng S, Liu X, Xu P, You R, Wang D, Liang S, Wu Y, Xu Y, Sun Q, Du S, Yuan Y, Deng G, Cheng J, Zhang D, Chen Q, Zhu X. Combination of multi-modal MRI radiomics and liquid biopsy technique for preoperatively non-invasive diagnosis of glioma based on deep learning: protocol for a double-center, ambispective, diagnostical observational study. Front Mol Neurosci. 2023 May 2;16:1183032. doi: 10.3389/fnmol.2023.1183032. eCollection 2023. PubMed 37201155 ↗

Individual participant data

Plan to share: Undecided — A reasonable request to share the original data of all glioma patients in this registry should be provided to the corresponding author

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2023, 14 months.

Of 115 non-industry observational studies under Glioma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 104. This study's 14 months is below that.

Counting every sponsor, half of 125 studies reached it within 60 months; a quarter within 29 and three quarters within 104.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2023 → Jul 2023, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2022
First posted
Sep 10, 2022
StartActual
May 1, 2022
Primary completionActual
Jul 28, 2023was May 2023
CompletionActual
Aug 30, 2023
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 20, 2026
Primary completion
May 1, 2023→Jul 28, 2023 (actual)
Oct 20, 2026
Enrollment
500 (estimated)→68 (actual)
Oct 20, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37201155 ↗
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37201155 ↗
    Primary completion May 1, 2023→Jul 28, 2023 (now actual)
    Enrollment 500 (estimated)→68 (actual)
    + 3 other changes: contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05536024
Lead sponsor
Second Affiliated Hospital of Nanchang University
Collaborators
Renmin Hospital of Wuhan University, Wuhan University
Responsible party
Sponsor
First posted
Sep 10, 2022
Start date
May 1, 2022
Primary completion
Jul 28, 2023
Completion
Aug 30, 2023
Last update
Oct 20, 2026

Study contacts

Xingen Zhu, Prof
study director · Second Affiliated Hospital of Nanchang University
Qianxue Chen
principal investigator · Renmin Hospital of Wuhan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion